Navigation Links
Fuld & Company Announces Appointment of MIT Fellow to Head Pharmaceutical Team's Strategic Gaming and Consulting Services
Date:12/16/2008

CAMBRIDGE, Mass., Dec. 16 /PRNewswire/ -- Fuld & Company today announced that Wayne Rosenkrans, Ph.D., will join the Company as vice president consulting, specializing in strategic gaming for the pharmaceutical and healthcare industries.

"We are excited to have Dr. Rosenkrans join the Fuld team," said Leonard Fuld, president. "His extensive accomplishment in the global pharmaceutical industry; government and academia -- coupled with his involvement on the cutting edge of personalized medicine -- makes him an extraordinary asset for our clients."

Fuld & Company's Pharmaceuticals Practice provides all levels of competitive support from research to consulting. The firm has serviced over 100 biotech, pharmaceutical and diagnostics/device companies for training, custom research, and systems consulting needs. Fuld assesses new product progress from early-stage development to product launch, technology partnerships between biotech and big pharma, as well as changing global technologies, regulations, and markets. The firm has researched over 60 different therapeutic categories worldwide.

Rosenkrans is a Distinguished Fellow at the Center for Biomedical Innovation at MIT working on healthcare strategy and policy issues related to science and medicine. He is also Chairman, President and a member of the board of directors of the Personalized Medicine Coalition, a Washington DC-based organization working with government and other agencies on evolving healthcare policy for Personalized Healthcare. He is also Chief Applications Officer for SciTech Strategies, focusing on scientific competency and capacity development for academia and industry.

Previously, Rosenkrans served as Director of External Relations for the Personalized Healthcare Team and Evidence-based Medicine (EBM) at AstraZeneca where he had responsibility for long-range external relations strategy and policy
'/>"/>

SOURCE Fuld & Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
2. Myngle Best ICT Company at the European Ventures Summit
3. SCRIP, the Leading Pharmaceutical Magazine in the World Crowns Glenmark as the "Best Pharma Company in the World - SME" and the "Best Company in Emerging Markets" at the SCRIP Awards 2008 in London
4. ProMetic signs $35 M Long-term Supply Agreement with European Biopharmaceutical company
5. CBDM.T, the Market and Business Intelligence Company Reviews the Biofuel Market
6. The Female Health Company Reports Record Results for Fiscal Year 2008, at High End of Guidance
7. CBDM.T, the Market and Business Intelligence Company Reviews the Biofuel Market
8. Laureate Pharma Honored as Emerging Life Sciences Company of the Year
9. Michigan Company Founded upon What Could Be History's Most Important Breakthrough in AI and Robotics
10. Genoptix Ranked Ninth Fastest-Growing Company in North America on Deloittes 2008 Technology Fast 500
11. West Michigans Newest Medical Device Company Receives Support from the West Michigan Science & Technology Initiative and EDF Ventures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 1000 balances – ... input on customers’ weighing needs and expertly narrows down ... of balances, scales or even terminals. , First, ... smallest weight (or select readability instead) and define the ... additional selection criteria narrows down the list to models ...
(Date:7/24/2014)... 2014   Cypher Genomics, Inc., the ... Adam Simpson as president and chief ... comprehensive annotation and interpretation of individual human genomes ... "Cypher,s technology has the potential to play a ... accuracy, optimizing therapeutic approaches and reducing adverse drug ...
(Date:7/23/2014)... Arab Emirates (UAE) (PRWEB) July 23, 2014 ... Century recently announced that its biobanking project, ... , Ph.D. to its growing Advisory Board. Scott ... very pleased to have Dr. Vaught onboard with Provia’s ... depth and expertise that Provia’s management team brings to ...
(Date:7/23/2014)... Dresden-Rossendorf (HZDR), the Vienna University of Technology and ... embedding nearly perfect semiconductor crystals into a silicon ... nanowires, very fast and multi-functional processing units can ... future. The research results will be published in ... are considered the cornerstone of future chip technology, ...
Breaking Biology Technology:Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4A crystal wedding in the nanocosmos 2
... SETAUKET, N.Y., May 25, 2011 John S. Kovach, ... Biotechnology Holdings, Inc. (LIXT.PK), announces the appointment of  Robert ... of Directors. Dr. Royds is Chair of ... a leading clinical research organization, which he founded in ...
... a Phase 2 multicenter, randomized, double-blind, proof-of-concept and ... 136) improved signs and symptoms of rheumatoid arthritis ... with methotrexate (MTX).  Findings from Part A of ... League Against Rheumatism (EULAR) Congress showed that a ...
... May 25, 2011 Watson Pharmaceuticals, Inc. (NYSE: ... today jointly announced that Watson has acquired the ... for EUR 400 million ($562 million) in cash ... the acquisition, Watson gains a leading generic product ...
Cached Biology Technology:Lixte Biotechnology Holdings Announces New Appointment to Board of Directors 2Lixte Biotechnology Holdings Announces New Appointment to Board of Directors 3Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis 2Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis 3Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis 4Watson Acquires Specifar Pharmaceuticals 2Watson Acquires Specifar Pharmaceuticals 3Watson Acquires Specifar Pharmaceuticals 4Watson Acquires Specifar Pharmaceuticals 5Watson Acquires Specifar Pharmaceuticals 6
(Date:7/24/2014)... , July 24, 2014 NXT-ID, Inc., (NXTD: OTCQB) a ... announces its next generation smart wallet, Wocket™, was recently the topic ... Finley interviewed Gino Pereira , CEO of ... minutes. Mr. Gino Pereira ... full of credit cards and walks host Anita ...
(Date:7/23/2014)... -- Pfenex Inc. (NYSE MKT: PFNX) today announced the pricing ... common stock at a price to the public of $6.00 ... 30-day option to purchase up to 1,250,000 additional shares of ... are expected to begin trading on the NYSE MKT on ... William Blair & Company, L.L.C. and JMP Securities LLC ...
(Date:7/23/2014)... or neglected early in life are at risk ... In a new study, scientists have found that ... has implications for children,s long-term development. Previous studies ... and genetics interacted with that child,s experiences in ... In the new study, researchers were able to ...
Breaking Biology News(10 mins):Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 2Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 4Pfenex Inc. Announces Pricing Of Initial Public Offering 2Stress tied to change in children's gene expression related to emotion regulation, physical health 2Stress tied to change in children's gene expression related to emotion regulation, physical health 3
... -- An Illinois research team has succeeded in ... that simultaneously reduces atmospheric carbon dioxide and produces ... engineering professor Paul Kenis and his research group ... startup company, to produce a catalyst that improves ...
... New Rochelle, NY, October 6, 2011Measurable changes in brain ... consequence of virus-induced injury during the early stages of ... implications in disease prognosis are detailed in an article ... Connectivity , a bimonthly peer-reviewed journal published by ...
... new research program funded by the National Institutes of ... has on human health. Led by NIH,s National Institute ... the risk factors that make people more vulnerable to ... such as air pollution and toxic chemicals; and the ...
Cached Biology News:Ionic liquid catalyst helps turn emissions into fuel 2Changes in brain function in early HIV infection: A reliable indicator of disease prognosis? 2NIH launches research program to explore health effects from climate change 2NIH launches research program to explore health effects from climate change 3
... Synaptogyrin 2 ( Abpromise ... Antigen: Synthetic ... sequence amino acids 42-57 of ... Entrez Gene ID: ...
Rabbit polyclonal to SMURF 2 ( Abpromise for all tested applications). Antigen: A KLH conjugated synthetic peptide (10-30 aa in length) at the N-term of first 50 aa of human SMURF 2. Entrez G...
Rabbit polyclonal antibody to NCOA2 [Agarose Immobilized]...
Rabbit anti Mouse ZIC2 Preservative: NaN3...
Biology Products: